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Purpose: To investigate the relationship of (lymph) angiogenesis and survival time of human cornea grafts.
Methods: This was a case series study. A total of 250 patients requiring a second keratoplasty were screened according
to our inclusion criteria: 1) only cases with primary non-inflamed cornea diseases were included; and 2) all primary
diseased  cornea  specimens  from  the  first  corneal  transplantation  were  confirmed  not  to  have  hemangiogenesis  or
lymphangiogenesis. The included patients were analyzed retrospectively and followed up for the survival time of the first
and second grafts. Blood vessel content (BVC) and lymphatic vessel content (LVC) were assessed in the primary diseased
cornea; first rejected grafts (including BVC1 and LVC1) and second rejected grafts (including BVC2 and LVC2) were
assessed by immunohistochemistry. The survival times of the first (STG1) and second (STG2) rejected corneal grafts were
calculated and the relationship between human corneal (lymph) angiogenesis and STG was statistically analyzed.
Results: After screening, only 23 patients (23 eyes) were included. Their primary cornea diseases were non-inflamed,
including keratoconus (n=14), leukoma (n=5), and Fuchs endothelial dystrophy (n=4). The mean duration of follow up
was 36 months after the second keratoplasty. In all, 55 cornea specimens from different times following penetrating
keratoplasty were collected and examined, including 23 primary non-inflamed corneas (without angiogenesis), 23 first
rejected corneal grafts (all with hemangiogenesis, but only six cases with blown lymphatic vessels), and nine rejected
corneal grafts (including six cases identified with lymphangiogenesis in the first rejection, all with lymphangiogenesis
and  hemangiogenesis).  Based  on  our  statistical  analysis,  STG1  was  correlated  with  LVC1  but  not  with  BVC1  or
(LVC1+BVC1), while STG2 was correlated with (LVC1+LVC2), LVC1, LVC2, (LVC2+BVC2) and (LVC1+BVC1) but not
with BVC1 or BVC2.
Conclusions: The survival time of human cornea grafts is related to both lymphangiogenesis and hemangiogenesis.
Lymphangiogenesis only occurred in some rejected cases, but it seems to be a signal of poor prognosis for the new allograft.
The major cause of corneal allograft failure is considered
to be immunological rejection [1-5], which depends on both
hemangiogenesis and lymphangiogenesis. These co-occur as
two arms of an immune reflex arc and accelerate immune
reactions leading to corneal rejection [6-8]. Numerous studies
have been conducted on the processes of corneal blood vessel
proliferation, whereas reports on corneal lymphangiogenesis
are  relatively  scarce,  especially  for  transplanted  human
corneas [8,9]. We previously reported that lymphangiogenesis
occurred after corneal transplantation in both rats and humans
[10]. However, without detailed clinical data, the relationship
of angiogenesis and graft survival time cannot be determined,
nor can the system (lymphatic system or blood vessels) that
plays the most important role in accelerating graft rejections
[5,11,12] be determined. In the present research, we began our
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clinical study by screening out cases of hospitalized patients
who had previously received penetrating keratoplasty because
of  non-inflamed  corneal  diseases  (taken  to  mean  no
hemangiogenesis or lymphangiogenesis) [13], but now have
experienced  corneal  graft  rejection  and  require  a  second
keratoplasty. All of the included patients were followed up
until the second corneal allograft failed and needed a third
transplantation or ophthalmectomy. Each cornea specimen
was assessed for blood vessel content (BVC) and lymphatic
vessel  content  (LVC)  by  immunohistochemistry  with
antibodies  specific  for  CD31  (vWF)  and  the  lymphatic
endothelial markers (lymphatic vessel endothelial hyaluronan
receptor [LYVE-1]). The survival time of the graft (STG) was
recorded  and  statistically  analyzed  together  with  the
pathology results.
METHODS
In total, 250 hospitalized patients, who required a second
keratoplasty because of graft failure occurring during January
2005 to December 2008, were screened. Only patients who
met the inclusion criteria were included in our study. The
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1694protocol  and  informed  consent  forms  were  reviewed  and
approved  by  the  Institutional  Review  Board/Ethics
Committee of Sun Yat-sen University and a written informed
consent form was completed by each study participant. The
study was conducted in accordance with the Declaration of
Helsinki  and  the  ethical  standards  of  the  local  ethics
committee.
Inclusion  criteria:  Primary  diseases  for  the  first
keratoplasty were non-inflamed cornea diseases. No systemic
immune diseases were found and no immunosuppressant was
used  preoperatively.  All  of  the  original  diseased  cornea
specimens (obtained from the first corneal transplantation)
from  the  included  patients  were  confirmed  to  be  without
hemangiogenesis  and  lymphangiogenesis  by
immunohistochemistry [6,14] and all cornea specimens were
identified  to  be  vWF-/LYVE-1-(Detailed  methods  are
described below). All of the patients received second or third
penetrating keratoplasty within one week after identification
of signs of graft rejection (The time interval between the first
and second, or second and third penetrating keratoplasty could
be considered as the survival time of the first or second corneal
allograft.). All of the diseased/rejected corneas were available
and were collected, and all of the included patients provided
signed consent and could be followed up according to our
schedule.
Surgical  and  clinical  follow-up  protocol:  Penetrating
keratoplasty was performed on all included patients according
to  standard  methods  [1]  and  they  received  the  same
immunosuppressive  agents  after  each  keratoplasty.  The
detailed regimen included:
1:  0.5%  Tacrolimus  Eye  Drops,  Qid  for  three
months;
2:  Compound  Tobramycin  Eye  Drops:  0.3%
tobramycin + 0.1% dexamethasone, Qid for one month;
3: Oral Predinisone 1mg/(kg/d), Qid, tapering by
20% every week, use for four weeks.
After  the  second  keratoplasty,  patients  were
followed  up  every  four  weeks  (one  month)  until  the
second corneal allograft failed and they required a third
transplantation or ophthalmectomy.
Immunohistochemistry: After corneas were sent to our
Ocular Pathology Laboratory for histopathologic evaluation,
they were fixed in 10% neutral formalin for 24 h, embedded
in paraffin and sectioned (4 μm sections: 20 sections were
from the central part of each cornea and the other 20 slices
were from peripheral part). All sections of rejected corneas
were rehydrated with graded ethanol-water mixtures, washed
with distilled water, and then endogenous peroxidase activity
was blocked by incubation with 30 ml/l hydrogen peroxidase
for 20 min. Every two neighboring sections were selected and
stained with streptavidin-biotin complex. The chosen cornea
sections  were  incubated  for  3  h  with  mouse  anti-human
LYVE-1 polyclonal antibody (R&D Systems, Minneapolis,
MN)  and  mouse  anti-human  cluster  of  differentiation  31
(CD31;  R&D  Systems).  The  slices  were  incubated  with
biotin-marked  rabbit  anti-mouse  immunoglobulin  (Boster,
Wuhan,  China)  as  the  secondary  antibody.  Finally,  after
incubation  with  streptavidin-biotin  horseradish  peroxidase
(SAB-HRP) complex (Boster) at room temperature for 30
min, the slides were visualized for peroxidase activity with
diaminobenzidine and counterstained with hematoxylin.
Lymphatic  vessel  content  and  blood  vessel  content:
Lymphatic vessel content (LVC) and blood vessel content
(BVC) of the human corneas were evaluated independently
by  two  observers  who  had  no  prior  knowledge  of  the
experimental details, and the evaluations were repeated twice.
The CD31(+) LYVE-1(-) stained vessels in cornea slices were
identified as blood vessels, whereas the CD31(+) LYVE-1(+)
vessels were identified as lymphatic vessels. Each cornea
sample was sliced into 40 slices (20 slices were from central
part and the other 20 slices were from peripheral part of each
cornea).  The  BVC  was  calculated  by  summing  all  blood
vessels in the 40 slices and dividing by 40. Similarly, LVC
was calculated by summing all lymphatic vessels in the 40
slices and dividing by 40 [6,8,14].
Statistics: Analysis of the significance of difference was
performed  using  the  paired  Student’s  t  test  for  normally
distributed data (BVC1, LVC1+BVC1 and STG1) and ANOVA
for  non-normally  distributed  data  (STG2,  BVC2,  LVC1,
LVC2, LVC2+BVC2; with the use of SPSS software [version
17.0; SPSS, Inc., Chicago, IL]). A multivariate model for STG
was  developed.  Values  are  presented  as  mean±SD.
Differences were accepted as significant when p<0.05.
RESULTS
Included  patients  cohort:  Screening  of  250  patients  with
corneal graft rejection identified only 23 patients (23 eyes, 15
male and 8 female; mean age, 50±14 years; range, 18–69) for
inclusion in the study. Primary non-inflamed cornea diseases
included  keratoconus  (n=14),  leukoma  (n=5),  and  Fuchs
endothelial dystrophy (n=4). After the second keratoplasty,
patients were followed up every month. The mean duration of
follow up was three years (average 36 months, 26–42 months)
after  the  second  keratoplasty.  In  nine  cases,  the  second
transplanted corneas were rejected during our follow up. (In
these 9 cases of second rejection, 4 patients received a third
corneal transplantation, but the other 5 patients had to undergo
ophthalmectomy for lack of any better choice.) The other 14
cases of second transplanted corneas are still functioning. In
all, 55 cornea specimens from penetrating keratoplasty or
ophthalmectomy,  including  23  non-vascularized  corneas
(primary  non-inflamed  diseases),  23  first  rejected  corneal
grafts, and nine rejected corneal grafts, were obtained for
examination in this study.
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the survival time of the first corneal allograft (STG1) was
estimated as the time interval between the first and second
penetrating  keratoplasty  (23  eyes,  18.478±7.089  months;
range, 3–33 months). In these 23 rejected allografts, 17 cases
presented mild hemangiogenesis (Figure 1A), but the other
six cases presented severe hemangiogenesis and inflammation
(Figure 1B), as determined by slit lamp examination. The
survival  time  of  the  second  corneal  graft  (STG2)  was
calculated as the time interval between the second and third
penetrating keratoplasty or ophthalmectomy (nine eyes were
rejected, 9.000±5.477months; range, 2–17 months; the other
14 cases are still functioning). In these second rejected cases,
four patients received a third corneal transplantation (Figure
1C), but the other five patients had to receive ophthalmectomy
(Figure 1D) for lack of a better choice.
Corneal  blood  and  lymphatic  vessels  in  rejected  cornea
grafts:  The  first  antibody  for  CD31  for
immunohistochemistry revealed a positive (brown) staining
for CD31 in lymphatic vessels and blood vessels (brown), as
shown in Figure 2A. The first antibody for LYVE-1 in a
neighboring cornea slice showed positive (brown) stain for
lymphatic  vessels  but  blood  vessels  were  negative  (no
staining) for LYVE-1, as shown in Figure 2B. The brown
corneal lymphangiogenesis appeared like vessels or strips,
along with blue vessels that were scattered within the positive
stroma  [6,8,10,14].  From  the  first  corneal  transplantation,
none of the primary cornea specimens with original diseases
showed hemangiogenesis or lymphangiogenesis. From the
second corneal transplantation, we found that 17 cases of the
first  rejected  cornea  that  presented  with  mild
hemangiogenesis  by  slip  lamp  examination  (Figure  1A),
which was confirmed by immunohistochemistry that showed
hemangiogenesis  occurring  and  inflammation  cells
infiltrating.  However,  the  other  6  cases  of  first  rejected
corneas  (Figure  1B)  showed  both  hemangiogenesis  and
lymphangiogenesis. All nine cases (Figure 1C,D) of second
rejected  transplanted  cornea  were  confirmed  to  show
hemangiogenesis and lymphangiogenesis.
Clinicopathological correlation: The relationships of STG,
hemangiogenesis, and lymphangiogenesis at different times
of corneal transplantation are shown in Figure 3.
The clinical data of STG1 and STG2 and the pathological
results of immunochemistry for LVC and BVC allowed us to
perform statistical analysis of the relationship of angiogenesis
and graft survival time and to determine which one (lymphatic
or  blood  vessels)  may  play  the  most  important  role  in
promoting corneal graft rejections. The paired Student t test
was used to compare the correlation between STG and LVC,
BVC  or  both  (Table  1).  The  STG1  showed  a  significant
correlation with LVC1 (Correlation=-0.577, p=0.004) but not
with  BVC1  or  (LVC1+BVC1);  STG2  has  a  significant
correlation with (LVC1+LVC2), LVC1, LVC2, (LVC2+BVC2)
and  (LVC1+BVC1)  (all  with  p<0.05,  and  the  correlation
coefficients were all negative, with values from largest to
smallest.) but not with BVC1 or BVC2 (p>0.05). Based on our
statistical analysis, we could see that the survival time of
human  cornea  grafts  (STG)  was  related  both  with
lymphangiogenesis (LVC) and hemangiogenesis (BVC), but
lymphangiogenesis (LVC) may play a more important role.
Figure  1.  Slit  lamp  photographs  of
different  rejected  corneal  grafts.  A:
Transplanted cornea was rejected with
slight  hemangiogenesis  occurring  and
light corneal edema, the iris and pupil
are difficult to discern. B: Transplanted
cornea was rejected and showed evident
hemangiogenesis  and  slight  corneal
edema, the iris and pupil were blurry but
could be distinguished. C: A rejected
transplanted  cornea  is  scattered  with
thick  hemangiogenesis;  the  iris  and
pupil cannot be seen. D: The rejected
cornea  had  a  perforation  with  thick
hemangiogenesis  and  severe  corneal
edema.
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A normal-risk keratoplasty usually has a successful outcome
and this is attributed to corneal immune privilege [5]. The lack
of both afferent lymphatic and efferent blood vessels in the
cornea prevents operation of either arm of an immune reflex
arc and is the most important cause of privilege among all
factors  [11,12,15,16].  For  a  high-risk  keratoplasty,
preexisting corneal stromal blood vessels have been identified
as a strong risk factor for immune rejection after corneal
transplantation, both in the clinical setting and in the well-
defined mouse model of corneal transplantation [11,15,17].
Recently, in addition to blood vessels (the efferent arm of an
immune reflex arc: access for immune effectors cells to the
graft),  lymphatic  vessels  that  are  microscopically
undetectable  have  been  found  in  association  with  blood
vessels in vascularized high-risk human corneas [8]. These
lymphatic vessels enable effective access of donor and host
antigen-presenting  cells  (APCs)  and  antigenic  material  to
regional lymph nodes, where accelerated sensitization to graft
Figure 2. Anti-LYVE-1 and anti-CD31 immunochemistry. A: Immunochemistry with CD31 as the first antibody. All vessels show brown
endothelium (red and green arrow). B: Immunochemistry with LYVE-1 as the first antibody; two vessels were the counterpart of the two in
the left figure, one shows a brown stained lymphatic vessel (green arrow), and the other one was inferred to be a blood vessel (red arrow).
C: Normal human cornea was absent of blood vessels and lymphatic vessels.
Figure 3. Schematic diagram of survival time of grafts (STG), hemangiogenesis and lymphangiogenesis detected at different times following
corneal transplantation.
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[5-8,18]. Yamagami et al. [19] have successfully inhibited
allograft rejection of mice after obstruction of corneal lymph
drainage  by  bilateral  cervical  lymphadenectomy  [20,21].
Their later study showed that the survival rate of corneal grafts
placed into vascularized recipient beds was as high as 92%21,
which  suggested  that  lymphangiogenesis  plays  a  more
important  role  in  allograft  rejection  than  does  corneal
hemangiogenesis in animal models.
Research  into  human  corneal  lymphangiogenesis  has
been scarce until now. Claus Cursiefen first reported that
lymphatic vessels existed in vascularized human corneas [8].
In his report, lymphatic vessels were found in 10 out of 21
cases  of  vascularized  human  corneas  caused  by  different
diseases. In our previous study [10], we also reported that
lymphangiogenesis  occurred  in  mouse  and  human
transplanted  corneas,  but  the  clinical  role  of
lymphangiogenesis  in  allograft  rejection  (accelerating  or
preventing rejection) still awaited identification [5,21]. Many
immunology related questions are still unanswered, such as:
whether  preexisting  corneal  stromal  blood  vessels  are  an
essential  condition  for  the  lymphangiogenesis  process;
whether lymphangiogenesis implies inevitable corneal graft
rejection; the nature of the relationship of angiogenesis and
graft survival time; and which (lymphatic or blood vessels)
may play a more important role in accelerating corneal graft
rejections. The present study was designed to answer these
questions by clinicopathological analysis of angiogenesis and
corneal graft rejection.
According  to  our  inclusion  criteria,  only  cases  with
primary non-inflamed cornea diseases were included. All of
the primary diseased cornea specimens from the first corneal
transplantation were confirmed to show no hemangiogenesis
or  lymphangiogenesis.  Therefore,  the  first  corneal
transplantation  could  be  considered  as  a  normal-risk
keratoplasty  and  preexisting  corneal  stromal  (lymph)
angiogenesis  is  apparently  not  an  essential  condition  for
allograft  rejection.  However,  for  the  second  corneal
transplantation, we found that 17 cases of rejected allografts
were confirmed with only hemangiogenesis occurring and
with  immunochemistry  showing  infiltration  with
inflammation cells, while six cases of rejected corneas showed
both hemangiogenesis and lymphangiogenesis processes. The
positive rate of lymphangiogenesis was 26.1%, which is much
lower than the value reported in vascularized human corneas
(48%) by Cursiefen et al. [8]. Two reasons may explain this:
First, all patients received a second penetrating keratoplasty
within one week of identifying the sign of the graft rejection,
so  the  time  may  be  not  have  been  long  enough  for
development  of  lymphangiogenesis.  Second,  the  primary
cornea  diseases  of  all  the  cases  in  our  study  were  non-
inflammatory,  without  hemangiogenesis  or
lymphangiogenesis. Lymphangiogenesis may be induced by
or  lead  to  allograft  rejection,  which  should  be  further
confirmed in the future study. Based on the third surgery, all
nine cases of second rejected allograft were confirmed with
hemangiogenesis and lymphangiogenesis. In these nine cases,
six cases had been identified with preexisting corneal stromal
hemangiogenesis  or  lymphangiogenesis  from  the  second
cornea transplantation, and the STG2 is obviously shorter than
the other allograft. Lymphangiogenesis only occurred in some
rejected cases, but it seems to be a signal of poor prognosis
for the new allograft.
We investigated the relationship of lymphangiogenesis
and corneal graft rejections further by statistical analysis of
the correlation of STG, LVC, and BVC of different corneal
allografts.  We  found  that  both  hemangiogenesis  and
lymphangiogenesis were significantly correlated with STG.
The second corneal grafts, in particular, when placed into
lymphatic-vascularized  recipient  beds,  would  fail  quickly
with  additional  and  more  severe  lymphangiogenesis  and
hemangiogenesis. In other words, similar to the implication
of lymphangiogenesis for tumor metastasis [13,22-24], new
allograft  rejection  is  predictable  and  inevitable  when
TABLE 1. CORRELATION BETWEEN STG AND LVC, BVC OR (LVC+BVC).
Variables Correlation coefficient Significance (p)
STG1 & LVC1 −0.577 0.004*
STG1 & BVC1 0.058 0.794
STG1 & (LVC1+BVC1) −0.249 0.251
STG2 & LVC2 −0.825 0.006*
STG2 & BVC2 −0.618 0.076
STG2 & (LVC2+BVC2) −0.821 0.007*
STG2 & LVC1 −0.885 0.002*
STG2 & BVC1 −0.125 0.794
STG2 & (LVC1+BVC1) −0.688 0.041*
STG2 & (LVC1+LVC2) −0.936 0.000*
         *When p<0.05, paired T-Test is significant and the correlation is accepted. †STG=The survival time of graft, LVC=Lymphatic
vessels counting, BVC=Blood vessels counting.     ††1 represents the first corneal allograft, 2 represents the second corneal allograft.
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25].
In conclusion, the survival time of a human cornea graft
is  associated  with  both  lymphangiogenesis  and
hemangiogenesis, and lymphangiogenesis is a signal of poor
prognosis for the new allograft.
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